FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 370 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... April 23, 2019 Women in science: Cancer research pioneers – part 2 January 25, 2023 EMA Recommends Extension of Therapeutic Indications for Selinexor June 15, 2022 ¿Puede el uso de un microondas causar cáncer? April 7, 2022 Load more HOT NEWS 10 Tips for Healthy Eating After Cancer Treatment Coping With War and Cancer: How to Take Care of Your... A new target to slow down ageing and reduce blood cancer... What the Reignited Cancer Moonshot Initiative Means for People With Cancer
